Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, Jan, Udeshi, Namrata D., Narla, Anupama, Grauman, Peter, Hurst, Slater N., McConkey, Marie, Svinkina, Tanya, Heckl, Dirk, Comer, Eamon, Li, Xiaoyu, Ciarlo, Christie, Hartman, Emily, Munshi, Nikhil, Schenone, Monica, Schreiber, Stuart L., Carr, Steven A., Ebert, Benjamin L.·2014·Science

DOI 10.1126/science.1244851

Cited by (1,006)

Items 301–400 of 1,006

Ikaros family zinc finger 1 regulates dendritic cell development and function in humans
Urszula Cytlak, Anastasia Resteu, Delfien Bogaert, Hye Sun Kuehn, Thomas Altmann, Andrew Richard Gennery, Graham Hunter Jackson, Attila Kumánovics, Karl V. Voelkerding, Seraina Prader et al. · 2018 · Nature Communications
Mapping the effects of drugs on the immune system
Brian A. Kidd, Aleksandra Wroblewska, Mary Regina Boland, Judith Agudo, Miriam Mérad, Nicholas P. Tatonetti, Brian D. Brown, Joel T. Dudley · 2015 · Nature Biotechnology
N -Myristoyltransferase Inhibition Induces ER-Stress, Cell Cycle Arrest, and Apoptosis in Cancer Cells
Emmanuelle Thinon, Julia Morales‐Sanfrutos, David J. Mann, Edward W. Tate · 2016 · ACS Chemical Biology
Gain-of-function IKZF1 variants in humans cause immune dysregulation associated with abnormal T/B cell late differentiation
Akihiro Hoshino, David Boutboul, Yuan Zhang, Hye Sun Kuehn, Jérôme Hadjadj, Nihal Özdemir, Tiraje Tülin Celkan, Christoph Walz, Capucine Pïcard, Christelle Lenoir et al. · 2022 · Science Immunology
UBE2G1 governs the destruction of cereblon neomorphic substrates
Lu, Gang, Weng, Stephanie, Matyskiela, Mary, Zheng, Xinde, Fang, Wei, Wood, Scott, Surka, Christine, Mizukoshi, Reina, Lu, Chin-Chun, Mendy, Derek et al. · 2018 · eLife
PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network
Reichermeier, Kurt M., Straube, Ronny, Reitsma, Justin M., Sweredoski, Michael J., Rose, Christopher M., Moradian, Annie, den Besten, Willem, Hinkle, Trent, Verschueren, Erik, Petzold, Georg et al. · 2020 · Molecular Cell
The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia
Hubo Li, Brenton G. Mar, Huadi Zhang, Rishi V. Puram, Francisca Vazquez, Barbara A. Weir, William C. Hahn, Benjamin L. Ebert, David S. Pellman · 2016 · Blood
Recent advances in the molecular mechanism of thalidomide teratogenicity
Gao, Shaobing, Wang, Shichao, Fan, Ruihua, Hu, Jieying · 2020 · Biomedicine & Pharmacotherapy
Multiple Myeloma Therapy: Emerging Trends and Challenges
Danai Dima, Dongxu Jiang, Divya Jyoti Singh, Metis Hasipek, Haikoo Shah, Fauzia Ullah, Jack Khouri, Jaroslaw Pawel Maciejewski, Babal Kant Jha · 2022 · Cancers
Protein Degradation via CRL4CRBN Ubiquitin Ligase: Discovery and Structure–Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1
Joshua D. Hansen, Kevin R. Condroski, Matthew Correa, George W. Muller, Hon‐Wah Man, Alexander L. Ruchelman, Weihong Zhang, Fan Vocanson, Tim Crea, Wei Liu et al. · 2017 · Journal of Medicinal Chemistry
Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors
Shuai Wang, Li-Jie Zhao, Yi‐Chao Zheng, Dandan Shen, Er-Fei Miao, Xue-Peng Qiao, Lijuan Zhao, Ying Min Liu, Ruilei Huang, Bin Yu et al. · 2016 · European Journal of Medicinal Chemistry
Molecular mechanisms of cereblon-based drugs
Tomoko Asatsuma‐Okumura, Takumi Ito, Hiroshi Handa · 2019 · Pharmacology & Therapeutics
A Chemical Biology View of Bioactive Small Molecules and a Binder‐Based Approach to Connect Biology to Precision Medicines
Stuart L. Schreiber · 2018 · Israel Journal of Chemistry
Plant ubiquitin ligases as signaling hubs
Nitzan Shabek, Ning Zheng · 2014 · Nature Structural & Molecular Biology
Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma
Ka Tat Siu, Janani Ramachandran, Andrew Jenho Yee, Homare Eda, Loredana Santo, Cristina Panaroni, Jennifer A. Mertz, Robert J. Sims, Michael Robert Cooper, Noopur S Raje · 2016 · Leukemia
Ceapins block the unfolded protein response sensor ATF6α by inducing a neomorphic inter-organelle tether
Torres, Sandra Elizabeth, Gallagher, Ciara M, Plate, Lars, Gupta, Meghna, Liem, Christina R, Guo, Xiaoyan, Tian, Ruilin, Stroud, Robert M, Kampmann, Martin, Weissman, Jonathan S et al. · 2019 · eLife
IRF4 in multiple myeloma—Biology, disease and therapeutic target
Alessandro Agnarelli, Timothy J. T. Chevassut, Erika J. Mancini · 2018 · Leukemia Research
A Metabolomics Approach to Pharmacotherapy Personalization
Elena E. Balashova, Dmitry L. Maslov, Petr G. Lokhov · 2018 · Journal of Personalized Medicine
Ubiquitin ligases in cancer: Functions and clinical potentials
Shanshan Duan, Michele Pagano · 2021 · Cell chemical biology
CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16
Andrea G. Shergalis, Violeta L. Marin, David Y. Rhee, Sameera Senaweera, Rebecca L. McCloud, Judith A. Ronau, Charles W. Hutchins, Shaun M. McLoughlin, Kevin R. Woller, Scott E. Warder et al. · 2023 · ACS Chemical Biology
Hypoxia-inducible KDM3A addiction in multiple myeloma
Sho Ikeda, Akihiro Kitadate, Fumito Abe, Naoto Takahashi, Hiroyuki Tagawa · 2018 · Blood Advances
Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171
Subramaniam, Agatheeswaran, Žemaitis, Kristijonas, Talkhoncheh, Mehrnaz Safaee, Yudovich, David, Bäckström, Alexandra, Debnath, Shubhranshu, Chen, Jun, Jain, Mayur Vilas, Galeev, Roman, Gaetani, Massimiliano et al. · 2020 · Blood
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
Xin Han, Lijie Zhao, Weiguo Xiang, Bukeyan Miao, Chong Qin, Mi Wang, Tianfeng Xu, Donna McEachern, Jianfeng Lü, Yu Wang et al. · 2023 · Journal of Medicinal Chemistry
Clec16a, Nrdp1, and USP8 Form a Ubiquitin-Dependent Tripartite Complex That Regulates β-Cell Mitophagy
Gemma L. Pearson, Biaoxin Chai, Tracy D. Vozheiko, Xueying Liu, Malathi Kandarpa, Robert C. Piper, Scott A. Soleimanpour · 2017 · Diabetes
Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs
Rishi R. Shah, Joanna M. Redmond, Andrei Mihut, Malini R. Menon, John P. Evans, John Anthony Murphy, Michelle A. Bartholomew, Diane M. Coe · 2020 · Bioorganic & Medicinal Chemistry
Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma
Nouf Alrasheed, Lydia S.H. Lee, Ehsan Ghorani, Jake Y. Henry, Lucía Conde, Melody Chin, Daria Galas‐Filipowicz, Andrew J.S. Furness, Selina J Chavda, Huw Richards et al. · 2020 · Clinical Cancer Research
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models
Shih‐Feng Cho, Liang Lin, Lijie Xing, Yuyin Li, Kenneth Wen, Tengteng Yu, Phillip A. Hsieh, Nikhil C. Munshi, Joachim Wahl, Katja Matthes et al. · 2020 · Blood Advances
De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives
Christopher Heim, Dimanthi Pliatsika, Farnoush Mousavizadeh, Kerstin Bär, Birte Hernandez Alvarez, Athanassios Giannis, Marcus D. Hartmann · 2019 · Journal of Medicinal Chemistry
A novel cereblon modulator for targeted protein degradation
Kim, Sung Ah, Go, Ara, Jo, Seung-Hyun, Park, Sun Jun, Jeon, Young Uk, Kim, Ji Eun, Lee, Heung Kyoung, Park, Chi Hoon, Lee, Chong-Ock, Park, Sung Goo et al. · 2019 · European Journal of Medicinal Chemistry
A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands
Bomie Han · 2020 · Journal of Biological Chemistry
Definition of a small core transcriptional circuit regulated by AML1-ETO
Kristy R. Stengel, Jacob D. Ellis, Clare Spielman, Monica L. Bomber, Scott W. Hiebert · 2020 · Molecular Cell
Single-cell epigenetic, transcriptional, and protein profiling of latent and active HIV-1 reservoir revealed that IKZF3 promotes HIV-1 persistence
Yulong Wei, Timothy C. Davenport, Jack A. Collora, Haocong Katherine Ma, Delia Pinto-Santini, Javier R. Lama, Ricardo Alfaro, Ann C. Duerr, Ya‐Chi Ho · 2023 · Immunity
Inducing protein-protein interactions with molecular glues
Ye Che, Adam M. Gilbert, Veerabahu Shanmugasundaram, Mark C. Noe · 2018 · Bioorganic & Medicinal Chemistry Letters
Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness
Asunción Espinosa-Sánchez, Elisa Suárez-Martínez, Laura Sánchez-Díaz, Amancio Carnero · 2020 · Frontiers in Oncology
RNA-binding protein 39: a promising therapeutic target for cancer
Caipeng Xu, Xiaohua Chen, Xuetian Zhang, Dapeng Zhao, Zhihui Dou, Xiaodong Xie, Hongyan Li, Hongying Yang, Qiang Li, Hong Zhang et al. · 2021 · Cell Death Discovery
Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands
Aleša Bricelj, Yuen Lam Dora Ng, Dominic Ferber, Robert D. Kuchta, Sina Müller, Marius Monschke, Karl Gerhard Wagner, Jan Krönke, Izidor Sosič, Michael Gütschow et al. · 2021 · ACS Medicinal Chemistry Letters
The Tao of myeloma
Lawrence Boise, Jonathan L. Kaufman, Nizar Jacques Bahlis, Sagar Lonial, Kelvin P. Lee · 2014 · Blood
RNA Polymerase I Inhibition with CX‐5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma
Hans Chulhee Lee, Hua Wang, Veerabhadran Baladandayuthapani, Heather Yan Lin, Jin He, Richard Julian Jones, Isere Kuiatse, Dongmin Gu, Zhiqiang Wang, Wencai Ma et al. · 2017 · British Journal of Haematology
Chemical Ligand Space of Cereblon
Iuliia Boichenko, Kerstin Bär, Silvia Deiss, Christopher Heim, Reinhard Albrecht, Andrei N. Lupas, Birte Hernandez Alvarez, Marcus D. Hartmann · 2018 · ACS Omega
Hydrophobic tag-based protein degradation: Development, opportunity and challenge
Qindi He, Xiaofei Zhao, Donglin Wu, Siming Jia, Canlin Liu, Zitian Cheng, Fei Huang, Yadong Chen, Tao Lu, Shuai Lü · 2023 · European Journal of Medicinal Chemistry
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi · 2024 · Lung Cancer
Monomeric Targeted Protein Degraders
Hanan, Emily J., Liang, Jun, Wang, Xiaojing, Blake, Robert A., Blaquiere, Nicole, Staben, Steven T. · 2020 · Journal of Medicinal Chemistry
Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
Yamanaka, Satoshi, Furihata, Hirotake, Yanagihara, Yuta, Taya, Akihito, Nagasaka, Takato, Usui, Mai, Nagaoka, Koya, Shoya, Yuki, Nishino, Kohei, Yoshida, Shuhei et al. · 2023 · Nature Communications
Opportunities and challenges of protein-based targeted protein degradation
Fangfang Shen, Laura M. K. Dassama · 2023 · Chemical Science
Computer-Aided Drug Discovery for Undruggable Targets
Qi Sun, Hanping Wang, Juan Xie, Liying Wang, Junxi Mu, Junren Li, Yuhao Ren, Luhua Lai · 2025 · Chemical Reviews
The emerging role for Cullin 4 family of E3 ligases in tumorigenesis
Ji Cheng, Jianping Guo, Brian J. North, Kaixiong Tao, Pengbo Zhou, Wenyi Wei · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
Klaus Podar, Xavier P Leleu · 2021 · Cancers
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
Yuen Lam Dora Ng, Evelyn Ramberger, Stephan Bohl, Anna Dolnik, Christian Steinebach, Theresia Conrad, Sina Müller, Oliver Popp, Miriam Kull, Mohamed Haji et al. · 2022 · Nature Communications
Induced protein degradation for therapeutics: past, present, and future
Hojong Yoon, Justine C. Rutter, Yen-Der Li, Benjamin L. Ebert · 2024 · Journal of Clinical Investigation
Malignant causes of fever of unknown origin
Vanessa Foggo, Jamie D. Cavenagh · 2015 · Clinical Medicine
Linking predation risk, ungulate antipredator responses, and patterns of vegetation in the high Andes
Emiliano Donadío, Steven W. Buskirk · 2016 · Journal of Mammalogy
IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma
Barrio, Santiago, Munawar, Umair, Zhu, Yuan Xiao, Giesen, Nicola, Shi, Chang-Xin, Viá, Matteo Da, Sanchez, Ricardo, Bruins, Laura, Demler, Theresa, Müller, Nicole et al. · 2020 · Haematologica
Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption
Phoebe K. Mondala, Ashni A. Vora, Tianyuan Zhou, Elisa Lazzari, Luisa Ladel, Xiaolin Luo, Youngsoo Kim, Caitlin L. Costello, A. Robert MacLeod, Catriona H. M. Jamieson et al. · 2021 · Cell stem cell
The rise of degrader drugs
Mingxing Teng, Nathanael S. Gray · 2023 · Cell chemical biology
Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity
Kenji Ichiyama, Jia Long, Yusuke Kobayashi, Yuji Horita, Takeshi Kinoshita, Yamami Nakamura, Chizuko Kominami, Katia Georgopoulos, Shimon Sakaguchi · 2024 · Immunity
The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice
Zubin Zhang, Jiefei Tong, Xiaowen Tang, Jiaxiang Juan, Biyin Cao, Rose Hurren, Guodong Chen, Paul P. Taylor, Xin Xu, Chang-Xin Shi et al. · 2016 · Blood
The Ubiquitin System in Immune Regulation
Yoon Park, Hyung‐seung Jin, Daisuke Aki, Jeeho Lee, Yun‐Cai Liu · 2014 · Advances in immunology
An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma
Ariosto Silva, Maria Cláudia Silva, Praneeth Reddy Sudalagunta, Allison I. Graeter, Timothy Jacobson, Aunshka Collins, Tuan Nguyen, Jinming Song, Dung‐Tsa Chen, Lu Chen et al. · 2017 · Cancer Research
FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor
Leili Ran, Yuedan Chen, Jessica J. Sher, Elissa W.P. Wong, Devan A. Murphy, Jenny Q. Zhang, Dan Li, Kemal Denız, Inna Sirota, Zhen Cao et al. · 2017 · Cancer Discovery
Bifunctional Small‐Molecule Ligands of K‐Ras Induce Its Association with Immunophilin Proteins
Zhang, Ziyang, Shokat, Kevan M. · 2019 · Angewandte Chemie International Edition
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
Franssen, Laurens E., Nijhof, Inger S., Couto, Suzana, Levin, Mark-David, Bos, Gerard M.J., Broijl, Annemiek, Klein, Saskia K., Ren, Yan, Wang, Maria, Koene, Harry R. et al. · 2018 · Haematologica
Immunotherapy in myeloma: how far have we come?
Laurens E. Franssen, Tuna Mutis, Henk M. Lokhorst, Niels W.C.J. van de Donk · 2019 · Therapeutic Advances in Hematology
Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy
Yunhua Peng, Jing Liu, Hiroyuki Inuzuka, Wenyi Wei · 2023 · Journal of Biological Chemistry
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, Chao Liang · 2023 · The Innovation
Quantitative Lys-ϵ-Gly-Gly (diGly) Proteomics Coupled with Inducible RNAi Reveals Ubiquitin-mediated Proteolysis of DNA Damage-inducible Transcript 4 (DDIT4) by the E3 Ligase HUWE1
Joel W. Thompson, Jane Nagel, Sjouke Hoving, Bertran Gerrits, Andreas Bauer, Jason R. Thomas, Marc W. Kirschner, Markus Schirle, Sarah J. Luchansky · 2014 · Journal of Biological Chemistry
Proteolysis-Targeting Chimeras: Harnessing the Ubiquitin-Proteasome System to Induce Degradation of Specific Target Proteins
Kevin G. Coleman, Craig M. Crews · 2017 · Annual Review of Cancer Biology
A MedChem toolbox for cereblon-directed PROTACs
Christian Steinebach, Izidor Sosič, Stefanie Lindner, Aleša Bricelj, Franziska Kohl, Yuen Lam Dora Ng, Marius Monschke, Karl Gerhard Wagner, Jan Krönke, Michael Gütschow · 2019 · MedChemComm
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
Jiro Kikuchi, Mitsuo Hori, Hidekatsu Iha, Noriko Toyama‐Sorimachi, Shotaro Hagiwara, Yoshiaki Kuroda, Daisuke Koyama, Tohru Izumi, Hiroshi Yasui, Atsushi Suzuki et al. · 2019 · Leukemia
Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries
Wang, Bo, Liu, Jin, Tandon, Ira, Wu, Suzhen, Teng, Peng, Liao, Jianhua, Tang, Weiping · 2021 · European Journal of Medicinal Chemistry
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
Teru Hideshima, Francesca Cottini, Hiroto Ohguchi, Jana Jakubı́ková, Güllü Görgün, Naoya Mimura, YT Tai, Nikhil C. Munshi, Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2015 · Blood Cancer Journal
Emerging drug development technologies targeting ubiquitination for cancer therapeutics
Gianluca Veggiani, María Carla Rosales Gerpe, Sachdev S. Sidhu, Wei Zhang · 2019 · Pharmacology & Therapeutics
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, Antonio Giovanni, Malerba, Eleonora, Leone, Patrizia, Prete, Marcella, Terragna, Carolina, Cavo, Michele, Racanelli, Vito · 2022 · Frontiers in Oncology
Peptidic degron for IMiD-induced degradation of heterologous proteins
Vidyasagar Koduri, Samuel K. McBrayer, Ella Liberzon, Adam C. Wang, Kimberly J. Briggs, Hyejin Cho, William G. Kaelin · 2019 · Proceedings of the National Academy of Sciences
Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
Haixiang Pei, Yangrui Peng, Qiuhua Zhao, Yihua Chen · 2019 · RSC Advances
Protein Engineering in the Ubiquitin System: Tools for Discovery and Beyond
Bo Zhao, Yien Che Tsai, Bo Jin, Bufan Wang, Yiyang Wang, Han Zhou, Tomaya Carpenter, Allan M. Weissman, Jun Yin · 2020 · Pharmacological Reviews
Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates
Hai‐Tsang Huang, Ryan J. Lumpkin, Ryan W. Tsai, Shuyao Su, Xu Zhao, Yuan Xiong, James Chen, Nada Mageed, Katherine A. Donovan, Eric S. Fischer et al. · 2024 · Nature Chemical Biology
The development of high-content screening (HCS) technology and its importance to drug discovery
Ivan Fraietta, Fabio Gasparri · 2016 · Expert Opinion on Drug Discovery
Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation
Qinglin Shi, Lijuan Chen · 2017 · Journal of Immunology Research
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
Adam Samuel Sperling, Michael W. Burgess, Hasmik Keshishian, Jessica A. Gasser, Shruti Bhatt, Max Jan, Mikolaj Michal Slabicki, Rob S. Sellar, Emma C. Fink, Peter Grant Miller et al. · 2019 · Blood
Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216
Teng, Mingxing, Lu, Wenchao, Donovan, Katherine A., Sun, Jialin, Krupnick, Noah M., Nowak, Radosław P., Li, Yen-Der, Sperling, Adam S., Zhang, Tinghu, Ebert, Benjamin L. et al. · 2022 · Journal of Medicinal Chemistry
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
Antonio Giovanni Solimando, Matteo Da Vià, Sebastiano Cicco, Patrizia Leone, Giuseppe Di Lernia, Donato Giannico, Vanessa Desantis, Maria Antonia Frassanito, Arcangelo Morizio, Julia Delgado Tascon et al. · 2019 · Journal of Clinical Medicine
Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91
Maha Hanafi, Xinde Chen, Nouri Neamati · 2021 · Journal of Medicinal Chemistry
Stopping the beating heart of cancer: KRAS reviewed
Lorenz Herdeis, Daniel Gerlach, Darryl B. McConnell, Dirk Kessler · 2021 · Current Opinion in Structural Biology
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
Huang, Shang-Yi, Lin, Chung-Wu, Lin, Hsiu-Hsia, Yao, Ming, Tang, Jih-Luh, Wu, Shang-Ju, Chen, Yao-Chang, Lu, Hsiao-Yun, Hou, Hsin-An, Chen, Chien-Yuan et al. · 2014 · Annals of Hematology
Ubiquitin diGLY Proteomics as an Approach to Identify and Quantify the Ubiquitin-Modified Proteome
Amit Fulzele, Eric J. Bennett · 2018 · Methods in molecular biology
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Huanjie Yang, Xin Chen, Kai Li, Hassan Ali Cheaito, Qianqian Yang, Guojun Wu, Jinbao Liu, Q. Ping Dou · 2019 · Seminars in Cancer Biology
Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology
Takumi Ito, Yuki Yamaguchi, Hiroshi Handa · 2021 · Cell chemical biology
Unveiling the hidden interactome of CRBN molecular glues
Kheewoong Baek, Rebecca J. Metivier, Shourya S. Roy Burman, Jonathan W. Bushman, Hojong Yoon, Ryan J. Lumpkin, Julia K. Ryan, Dinah M. Abeja, Megha Lakshminarayan, Hong Yue et al. · 2025 · Nature Communications
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
Gunilla Enblad, Hannah Karlsson, Angelica Loskog · 2015 · Human Gene Therapy
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
Teru Hideshima, Daisuke Ogiya, Jiye Liu, Takeshi Harada, Keiji Kurata, Jooeun E. Bae, Walter W. Massefski, Kenneth Carl Anderson · 2020 · Leukemia
The Cullin 4A/B-DDB1-Cereblon E3 Ubiquitin Ligase Complex Mediates the Degradation of CLC-1 Chloride Channels
Chen, Yi-An, Peng, Yi-Jheng, Hu, Meng-Chun, Huang, Jing-Jia, Chien, Yun-Chia, Wu, June-Tai, Chen, Tsung-Yu, Tang, Chih-Yung · 2015 · Scientific Reports
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities
Athena Kritharis, Michael Coyle, Jaya Sharma, Andrew M. Evens · 2015 · Blood
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
Michael Heider, Ruth Eichner, Jacob Stroh, Volker Morath, Anna Kuisl, Jana Zecha, Jannis Lawatscheck, Kheewoong Baek, Anne-Kathrin Garz, Martina Rudelius et al. · 2021 · Molecular Cell
Ubiquitin proteasome system in immune regulation and therapeutics
Sameer Ahmed Bhat, Zahra Vasi, Ritika Adhikari, Anish Gudur, Asceal Ali, Liping Jiang, Rachel Ferguson, David Liang, Shafi Kuchay · 2022 · Current Opinion in Pharmacology
Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins
Junius Eugene Thomas, Mi Wang, Wei Jiang, Meilin Wang, Lu Wang, Bo Wen, Duxin Sun, Shaomeng Wang · 2023 · Journal of Medicinal Chemistry
How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Arnon Philip Kater, Sanne H. Tonino, Alexander Egle, Alan G. Ramsay · 2014 · Blood
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
Ajai Chari, Hearn Jay Cho, Amishi Dhadwal, Gillian Morgan, Lisa La, Katarzyna Zarychta, Donna Catamero, Erika Florendo, Nadege Stevens, Daniel Verina et al. · 2017 · Blood Advances
Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients
Sridurga Mithraprabhu, Rachel Morley, Tiffany T. Khong, Anna Kalff, Krystal Bergin, Jay Hocking, Ioanna Savvidou, Kathryn M. Bowen, Malarmathy Ramachandran, Kawa Choi et al. · 2019 · Leukemia
Molecular glue concept solidifies
Kheewoong Baek, Brenda Arlene Schulman · 2019 · Nature Chemical Biology
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
Nan Zhou, Álvaro Gutiérrez-Uzquiza, Xiang Yu Zheng, Renxu Chang, Dan T. Vogl, Alfred L. Garfall, Luca L Bernabei, Anita Saraf, Laurence A. Florens, Michael P. Washburn et al. · 2019 · Leukemia